BioCentury | Feb 2, 2009
Clinical News

Alagebrium: Phase II discontinued

...160 patients to evaluate 20 mg of oral alagebrium given twice daily for 6 months. Synvista Therapeutics Inc....
BioCentury | Feb 2, 2009
Clinical News

SYI-2074: Phase II discontinued

...to SYI-2074 from Oxis. Novel Therapeutic developed the topical cream formulation of the product for Synvista...
...Novel Therapeutic Technologies Inc. , Wilmington, Del. Oxis International Inc. (OTCBB:OXISE; Euronext:OXI), Foster City, Calif. Synvista Therapeutics Inc....
BioCentury | Feb 2, 2009
Company News

Synvista diagnostic news

...Synvista Therapeutics Inc. (AMEX:SYI), Montvale, N.J. Business: Diagnostic Synvista will end its ongoing clinical trials of...
...end its ongoing clinical trials of therapeutics to focus on diagnostics and explore strategic alternatives. Synvista...
...FDA for the Haptochek test kit to identify diabetic patients with haptoglobin 2-2 (Hp2-2) genotype. Synvista...
BioCentury | Feb 2, 2009
Clinical News

Alagebrium: Phase II discontinued

...evaluate 200 mg of oral alagebrium given twice daily for 9 months in 102 patients. Synvista Therapeutics Inc....
BioCentury | Jan 19, 2009
Clinical News

Alagebrium: Completed Phase II enrollment

...II BENEFICIAL trial evaluating 200 mg of oral alagebrium given twice daily for 9 months. Synvista Therapeutics Inc....
BioCentury | Jan 12, 2009
Finance

2009 milestones

...data 2009 Synta (NASDAQ:SNTA)/ GSK (LSE:GSK; NYSE:GSK) Elesclomol (formerly STA-4783) Metastatic melanoma Submit NDA 2H09 Synvista...
BioCentury | Jan 5, 2009
Clinical News

CML Assay diagnostic data

...was measured with Synvista's CML Assay. Data were published in the European Journal of Nutrition. Synvista Therapeutics Inc....
BioCentury | Jan 5, 2009
Clinical News

CML Assay diagnostic data

...was measured with Synvista's CML Assay. Data were published in the American Journal of Hypertension. Synvista Therapeutics Inc....
BioCentury | Dec 22, 2008
Clinical News

SYI-2074: Phase II started

...Synvista began a double-blind, placebo-controlled, Israeli Phase II trial of topical SYI-2074 in 30 patients. Synvista...
...to SYI-2074 from Oxis. Novel Therapeutic developed the topical cream formulation of the product for Synvista...
...Novel Therapeutic Technologies Inc. , Wilmington, Del. Oxis International Inc. (OTCBB:OXISE; Euronext:OXIS), Foster City, Calif. Synvista Therapeutics Inc....
BioCentury | Nov 24, 2008
Clinical News

Haptochek regulatory update

...company said diabetic patients with the Hp2-2 genotype have a higher risk of cardiovascular complications. Synvista Therapeutics Inc....
Items per page:
1 - 10 of 207
BioCentury | Feb 2, 2009
Clinical News

Alagebrium: Phase II discontinued

...160 patients to evaluate 20 mg of oral alagebrium given twice daily for 6 months. Synvista Therapeutics Inc....
BioCentury | Feb 2, 2009
Clinical News

SYI-2074: Phase II discontinued

...to SYI-2074 from Oxis. Novel Therapeutic developed the topical cream formulation of the product for Synvista...
...Novel Therapeutic Technologies Inc. , Wilmington, Del. Oxis International Inc. (OTCBB:OXISE; Euronext:OXI), Foster City, Calif. Synvista Therapeutics Inc....
BioCentury | Feb 2, 2009
Company News

Synvista diagnostic news

...Synvista Therapeutics Inc. (AMEX:SYI), Montvale, N.J. Business: Diagnostic Synvista will end its ongoing clinical trials of...
...end its ongoing clinical trials of therapeutics to focus on diagnostics and explore strategic alternatives. Synvista...
...FDA for the Haptochek test kit to identify diabetic patients with haptoglobin 2-2 (Hp2-2) genotype. Synvista...
BioCentury | Feb 2, 2009
Clinical News

Alagebrium: Phase II discontinued

...evaluate 200 mg of oral alagebrium given twice daily for 9 months in 102 patients. Synvista Therapeutics Inc....
BioCentury | Jan 19, 2009
Clinical News

Alagebrium: Completed Phase II enrollment

...II BENEFICIAL trial evaluating 200 mg of oral alagebrium given twice daily for 9 months. Synvista Therapeutics Inc....
BioCentury | Jan 12, 2009
Finance

2009 milestones

...data 2009 Synta (NASDAQ:SNTA)/ GSK (LSE:GSK; NYSE:GSK) Elesclomol (formerly STA-4783) Metastatic melanoma Submit NDA 2H09 Synvista...
BioCentury | Jan 5, 2009
Clinical News

CML Assay diagnostic data

...was measured with Synvista's CML Assay. Data were published in the European Journal of Nutrition. Synvista Therapeutics Inc....
BioCentury | Jan 5, 2009
Clinical News

CML Assay diagnostic data

...was measured with Synvista's CML Assay. Data were published in the American Journal of Hypertension. Synvista Therapeutics Inc....
BioCentury | Dec 22, 2008
Clinical News

SYI-2074: Phase II started

...Synvista began a double-blind, placebo-controlled, Israeli Phase II trial of topical SYI-2074 in 30 patients. Synvista...
...to SYI-2074 from Oxis. Novel Therapeutic developed the topical cream formulation of the product for Synvista...
...Novel Therapeutic Technologies Inc. , Wilmington, Del. Oxis International Inc. (OTCBB:OXISE; Euronext:OXIS), Foster City, Calif. Synvista Therapeutics Inc....
BioCentury | Nov 24, 2008
Clinical News

Haptochek regulatory update

...company said diabetic patients with the Hp2-2 genotype have a higher risk of cardiovascular complications. Synvista Therapeutics Inc....
Items per page:
1 - 10 of 207